Introduction
============

Ventilator-associated pneumonia (VAP) is a special form of hospital-acquired pneumonia, and is a common complication of ventilator use in intensive care units. This condition is also associated with increased mortality, extended hospital stays, and additional medical costs ([@B17]; [@B1]; [@B25]). According to earlier research ([@B29]), the overall prevalence of ICU infection was 51% (7087/13796), and the usage rate of antibacterial drugs was 71%; meanwhile, 56% of ICU patients received mechanical ventilation, and the infection rate among them was 67.6%. Over the years, the incidence of VAP and the risk of VAP-related death have been reduced, with a recent estimate of 9--13%, mainly due to the implementation of prevention strategies ([@B16]; [@B7]). Studies have shown that the total costs of hospitalization for patients with VAP are twice those of patients without VAP ([@B24]). Given the enormous burdens caused by this disease and its resulting mortality, many studies have focused on its accurate diagnosis, treatment and prevention around the world.

The outcome of drug therapy for VAP mainly depends on the application of antibacterial drugs. The pathogens of VAP are complex and diverse, and drug resistance appears quite frequently. Demands for antibacterial drugs are high, but serious unreasonable applications also simultaneously emerge in drug uses. According to relevant statistics, among the applications of antibacterial drugs in the ICU, 30--60% are unnecessary, inappropriate or undesirable, and about 50% of the ICU antibiotic prescriptions are for the treatment of VAP ([@B15]). A statistical analysis by the Johns Hopkins University School of Medicine in the United States showed that patients without VAP or other infections received needless antibiotics treatments of 1 183 days during the study period ([@B20]). Proper use of antibacterials will reduce hospital stays and hospitalization costs.

Bibliometric analysis is a method assessing the status and trends of a particular research field and thus providing ideas and directions for future research. Bibliometric studies have offered insights for some special conditions, including respiratory disease ([@B26]), coronary heart disease ([@B13]), and hypertension ([@B21]). However, there has been no comprehensive review of studies on drug treatment for VAP using bibliometric methods.

The purpose of this study was to use bibliometric methods to analyze the 100 most cited articles on drug therapy for VAP, hoping to gain a deeper understanding on research status through analyzing their publication year, author, affiliations, country, journal and other key features.

Materials and Methods {#s1}
=====================

Data Sources
------------

The most cited VAP-related articles were retrieved from the Institute for Scientific Information (ISI) Web of Science core collection database from the beginning of the database to September 30, 2018 (updated to November 1, 2018), at Henan University, Kaifeng, Henan. VAP, drug therapy, and antibiotics were used as search terms. Articles were sorted in descending order according to the number of times cited, and 100 articles most cited were determined.

Data Extraction
---------------

Two independent researchers evaluated each identified article to ensure that the article involved drug therapy for VAP, regardless of the article type. The following information was collected from the included articles: authors, year of publication, title, journal, article type, author's affiliations, country, citation frequency.

Statistical Analysis
--------------------

Microsoft Excel 2013 software was used for descriptive statistical analysis of author's affiliations, country, journal, and the number of citations; VOSviewer 1.6.8 software ([@B28]) was used for visual analysis, mapping network diagram of keyword co-occurrences and co-authored researchers. In the terms' map, each circle represented a term. The size of the circle indicated how often it appeared. The color of a circle indicated the average number of citations received. If they appeared together in any of the 100 articles, one line connected the two circles, and the thicker the line was, the more times they appeared together. If two terms appeared more frequently together, two circles would be closer. The term map visualization appears in at least five times of the 100 articles.

Results
=======

The 100 most-cited manuscripts were mainly original articles (53%) and reviews (38%), and few of them were proceedings papers (9%). The total number of citations for each article ranged from 142 to 3,218, and the mean number of citations was 351.82. Nearly one-third of articles (*n* = 30) showed more than 300 citations, and only five articles were cited more than 1,000 times. These top 100 most-cited articles were published between the years of 2000 and 2016. The most recent one was published in September 2016 with 367 citations (20th in the Top 100), and functions as a clinical practice guide for the management of hospital-acquired and VAP in adults from the American Society of Infectious Diseases and the American Thoracic Society, which was published by [@B10] in *Clinical Infectious Diseases*. [Supplementary Table S1](#SM1){ref-type="supplementary-material"} shows the data for the top 100 cited articles evaluated in the present study.

The top 100 articles are from 20 countries. Only the United States (*n* = 35) and France (*n* = 12) contributed more than 10 articles, followed by Greece (*n* = 7), Australia (*n* = 6), Canada (*n* = 6), and the Netherlands (*n* = 5) and Switzerland (*n* = 5). The countries from which the Top 100 article originated and the number of our collected articles, from each of those countries are shown in [Figure 1](#F1){ref-type="fig"}.
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The University of Washington produced 32% of the top 100 articles, followed by The University of Queensland (6%), Canada's McMaster University (5%), Australia's Royal Brisbane and Women's Hospital (5%) and Tufts University (5%) ([Table 1](#T1){ref-type="table"}).

###### 

Institutions contributing to the 100 most-cited articles.

  Institution name                            Number of articles
  ------------------------------------------- --------------------
  Washington University                       32
  The University of Queensland                6
  McMaster University                         5
  Royal Brisbane and Women's Hospital         5
  Tufts University                            5
  Queens University                           4
  The Alfa Institute of Biomedical Sciences   3
  Harvard University                          3
  Henry Dunant Hospital                       3
  Bichat-Claude Bernard Hospital              3
                                              

The top 10 authors most listed in the top 100 articles are summarized in [Table 2](#T2){ref-type="table"}. The list was led by Marin H. Kollef from the University of Washington's St. Louis School of Medicine, who wrote 16 of the top 100 articles; meanwhile, three other authors in the list also came from the same university, two authors following Marin H. Kollef were from the University of Queensland. All of the hospitals in the list are teaching hospitals.

###### 

Top 10 authors most frequently appearing in the articles.

  Author        Number of articles   Affiliation                             Country
  ------------- -------------------- --------------------------------------- ---------------
  Kollef MH     16                   Washington University                   United States
  Fraser V      7                    Washington University                   United States
  Chastre J     6                    Groupe Hospitalier Pitié-Salpêtrière    France
  Roberts JA    6                    University of Queensland                Australia
  Ward S        5                    Washington University                   United States
  Lipman J      5                    University of Queensland                Australia
  Sherman G     4                    Washington University                   United States
  Muscedere J   4                    Queens University                       Canada
  Falagas ME    4                    Alfa Institute of Biomedical Sciences   Greece
  Fagon J       3                    Hôpital européen Georges-Pompidou       France
                                                                             

The top 100 articles were published in 31 journals with influence factors ranging from 0 to 79.258 (mean ±± SD: 13.324 ± 15.562). Half of the 100 articles were published in journals of critical care (*n* = 41) or infectious diseases (*n* = 24). The journals ([Table 3](#T3){ref-type="table"}) which published the top 100 articles are led by *Critical Care Medicine* (*n* = 17), *American Journal of Respiratory and Critical Care Medicine* (*n* = 11), *Clinical Infectious Diseases* (*n* = 10) and *Chest* (*n* = 8). These are top journals in the field of critical care and infectious disease.

###### 

Journals of the 100 most-cited articles.

  Journal                                                                             No. of articles   Citation count   Country         Impact factor   Quartile in category^\$^
  ----------------------------------------------------------------------------------- ----------------- ---------------- --------------- --------------- --------------------------
  *Critical Care Medicine*                                                            17                3,671            United States   6.630           Q1
  *American Journal of Respiratory and Critical Care Medicine*                        11                7,511            United States   15.239          Q1
  *Clinical Infectious Diseases*                                                      10                6,048            United States   9.117           Q1
  *Chest*                                                                             8                 2,940            United States   7.652           Q1
  *Antimicrobial Agents and Chemotherapy*                                             4                 1,660            United States   4.255           Q1
  *Annals of Internal Medicine*                                                       4                 1,496            United States   19.384          Q1
  *Lancet*                                                                            3                 1,264            ENGLAND         53.254          Q1
  *New England Journal of Medicine*                                                   3                 1,251            United States   79.258          Q1
  *Lancet Infectious Diseases*                                                        3                 748              United States   25.148          Q1
  *Clinical Microbiology Reviews*                                                     3                 719              United States   20.642          Q1
  *Journal of Antimicrobial Chemotherapy*                                             3                 641              ENGLAND         5.217           Q1
  *Clinical Pharmacokinetics*                                                         3                 543              NEW ZEALAND     4.464           Q1
  *Critical Care*                                                                     3                 533              ENGLAND         6.425           Q1
  *International Journal of Antimicrobial Agents*                                     3                 529              NETHERLANDS     4.253           Q1
  *American Journal of Infection Control*                                             2                 509              United States   1.929           Q3
  *Clinical Microbiology and Infection*                                               2                 507              ENGLAND         5.394           Q1
  *Journal of Hospital Infection*                                                     2                 470              ENGLAND         3.354           Q2
  *Expert Review of Anti-Infective Therapy*                                           2                 361              ENGLAND         3.141           Q2
  *European Respiratory Journal*                                                      2                 329              ENGLAND         12.242          Q1
  *Jama-Journal of the American Medical Association*                                  1                 711              United States   47.661          Q1
  *Nature Reviews Microbiology*                                                       1                 536              ENGLAND         31.851          Q1
  *American Journal of Medicine*                                                      1                 404              United States   5.117           Q1
  *Fems Yeast Research*                                                               1                 317              ENGLAND         2.609           Q2
  *Molecular Microbiology*                                                            1                 242              United States   3.816           Q2
  *Intensive Care Medicine*                                                           1                 200              United States   15.008          Q1
  *British Medical Journal*                                                           1                 199              ENGLAND         23.259          Q1
  *Proceedings of the National Academy of Sciences of the United States of America*   1                 190              United States   9.504           Q1
  *Journal of Critical Care*                                                          1                 178              United States   2.872           Q2
  *Plos One*                                                                          1                 157              United States   2.766           Q1
  *Current Opinion in Infectious Diseases*                                            1                 162              United States   3.782           Q2
  *Archives of Internal Medicine*                                                     1                 156              United States   8.762^\#^       Q1^\#^
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Fifty-one terms or phrases appeared five times or more in the titles or abstracts of the top 100 articles ([Figure 2](#F2){ref-type="fig"}). For example, "VAP" appeared 81 times, "intensive care unit" 56 times, "critically ill patients" 37 times, "nosocomial pneumonia" 19 times, while "mortality" and "blood-stream infections" 17 times. Accordingly, the terms or phrases associated with VAP are divided into four clusters, represented by four colors (red, green, blue and orange). As shown in [Figure 2](#F2){ref-type="fig"}, many terms may reflect VAP-related content, such as: epidemiology, Gram-negative bacilli, infection, community-acquired pneumonia, pseudomonas-aeruginosa, etc. From these terms, we could find that the current attentions of drug therapy for VAP mainly focus on clinical application of antibacterial drugs, the types of pathogenic bacteria, epidemiological investigations and the standardization of clinical treatment. The 20 terms or phrases that appeared most frequently are listed in [Table 4](#T4){ref-type="table"}. After scoring the average publication year of the documents in which a keyword or a term occurs, we found some terms, like pseudomonas-aeruginosa bacteremia, Gram-negative bacteria, beta-lactam antibiotics, metallo-beta-lactamase, blood-stream infections becomes the hotspots in the field of VAP.

![Network visualization using words from the titles and abstracts of the 100 most-cited articles.](fphar-10-00108-g002){#F2}

###### 

Top 20 terms with most frequent occurrence in the titles or abstract.

  Keywords                             Occurrences   Total link strength
  ------------------------------------ ------------- ---------------------
  Ventilator-associated pneumonia      81            394
  Intensive care unit                  56            310
  Critically ill patients              37            205
  Nosocomial pneumonia                 19            102
  Mortality                            17            108
  Blood-stream infections              17            74
  Epidemiology                         14            92
  Gram-negative bacilli                14            71
  Infection                            13            85
  Community-acquired pneumonia         13            62
  Pseudomonas-aeruginosa               13            53
  Therapy                              11            80
  Sepsis                               11            62
  Mechanical ventilation               10            67
  Inadequate antimicrobial treatment   10            65
  Respiratory-tract infections         10            52
  Risk-factors                         10            52
  Diagnosis                            9             63
  Nosocomial infections                9             62
  Impact                               9             58
                                                     

Discussion
==========

In this study, we identified and analyzed the 100 most-cited articles in the field of drug therapy for VAP. The purpose of this bibliometric analysis was to assess the status and trends of the most-cited articles in the field of drug therapy for VAP.

Most of the 100 articles were from European countries and the United States, and only three were from Asian countries. Possible reason for this phenomenon may be that the definition of VAP is slightly different between countries or organizations ([@B10]; [@B27]). Currently, these has been no gold standard for VAP diagnosis. The causes of this condition in different regions and hospitals are different, and the bacterial spectrum also varies between patients and ICUs. Up to now, VAP is usually diagnosed through combining the result from positive bacterial culture with patients' clinical symptoms, and antibiotics for treatment would be determined based on the results of drug susceptibility tests ([@B18]; [@B22]).

The number of citations for the Top 100 articles ranged from 142 to 3,218. Compared with other specialties ([@B21]; [@B26]; [@B13]), the number of citations was not large, probably because our research topic only involves a part of the respiratory system and critical care. However, considering physical, psychological and economic burdens from VAP on patients, study on drug therapy for VAP is also very important.

The Top 100 articles were published in 31 journals. Among the journals, 2 core ones published 28 papers, in addition, 26 articles were published in 4 journals, 24 articles were published in 8 journals and 22 articles were published in 17 journals. This journals are sorted by number of articles into four groups, each with about quarter of all articles (28:26:24:22), then the number of journals in each group will be proportional to1:2:2^2^:2^3^ (2:4:8:17). This distribution of the publications was consistent with Bradford's law ([@B5]). Ninety percent of the top 100 articles were published in journals of the Q1 from Journal Citation Reports 2017 edition. These journals are generally the top ones of the profession or the medicine field. These journals with high impact factor attract higher quality papers, and their publications of excellent articles can further elevate their academic influence in turn ([@B6]).

According to the results on keyword co-occurrence, the top 100 most-cited articles covered a wide range of topics, including all aspects of drug-treated VAP, such as VAP risk factors ([@B8]), pathogen production, VAP prevention ([@B19]), diagnosis ([@B9]), treatment using antibiotics ([@B2]), rational use of antibiotics ([@B4]), mortality ([@B3]), the investigation on VAP epidemics ([@B11]), and the burden of the disease ([@B24]). Patients in ICU always have low immunity, suffering endogenous infections; meanwhile, VAP pathogens are highly resistant to antibiotics ([@B30]). Studies ([@B14]; [@B23]) have found that C-reactive protein (CRP) and procalcitonin (PCT) can be used as screening methods for VAP, and that when combining PCT with Clinical Pulmonary Infection Scores (CPIS), the diagnostic specificity for VAP can reach 100%. At the same time, the decline of CRP is closely related to the application of appropriate antibiotic treatment. Therefore, VAP prevention, early diagnosis and appropriate treatment measures are key to reduce the mortality and medical burden. High-quality training of ICU medical staffs to strengthen preventive measures for VAP-related pathophysiology can effectively reduce the occurrence of complications. In recent years, a practitioner of critical care medicine can focus on the treatment of Gram-negative bacteria, such as Pseudomonas aeruginosa, by combined use of antibiotics, and explore the mechanism of antibiotic resistance acquisition.

We acknowledge that this study has some limitations. We only searched the ISI Web of Science core collection database, with other databases such as PubMed and Scopus unsearched, and the final results were also affected by the search strategy and inclusion/exclusion criteria. Some of influential articles may be missed in our bibliometric analysis. Since the citation frequency of an article is influenced by many factors, such as the influence of journals, authors, institutions, etc., the academic influence of articles cannot be reflected only by their cited times. In addition, the citation frequency of earlier published articles should be more than that of recently published ones ([@B12]), though academic influence of former ones may be not necessarily heavier than that of latter ones. Hence, academic impact should be simultaneously adjudged for multiple parameters, such as H-index and citation density. There were also publication bias and/or language biases in our research. Despite these limitations, we did provide insights into the development and characteristics of drug therapy for VAP.

Conclusion
==========

In this study, we analyzed the top 100 most-cited articles on drug therapy for VAP via bibliometrics. These top 100 articles were published after the year 2000 in top journals in the field of critical care medicine and respiratory systems. Clinical trials and antibacterial usage are the main topics of these articles, which contribute to the development and optimization of antibiotics' application. The United States and France produced the most highly cited papers in VAP. Prof Marin H. Kollef was the author of the most papers in the top 100 in VAP. This report provides insights into historical developments and characteristics of the most-cited articles on drug therapy for VAP.
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